CF
DNLI icon

Corebridge Financial’s Denali Therapeutics DNLI Stock Holding History

Corebridge Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,898
Closed -$828K – 786
2025
Q1 		$828K Sell
60,898
-902
-1% -$17.3K ﹤0.01% 1349
2024
Q4 		$1.26M Sell
61,800
-4,665
-7% -$119K 0.01% 1227
2024
Q3 		$1.94M Sell
66,465
-410
-0.6% -$10.2K 0.01% 1055
2024
Q2 		$1.55M Buy
+66,875
New +$1.28M 0.01% 1104

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corebridge Financial's DNLI Position: Q2 2025 in Review

Corebridge Financial sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 60,898 shares — an estimated $828K sold.

Corebridge Financial first reported a position in DNLI in Q2 2024 and held it in 4 quarters. The position peaked at $1.94M in Q3 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Corebridge Financial reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 60,898 Denali Therapeutics shares in Q2 2025, an estimated $828K.
  • Corebridge Financial first reported a position in Denali Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Denali Therapeutics position peaked at $1.94M in Q3 2024.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.